Jenoptik (JEN) Corporate presentation summary

Company overview and strategy

• Global photonics group with ~4,500 employees, €1.05bn revenue in 2025, and 18.4% EBITDA margin.

• Focused on semiconductor technology, medical technology, metrology, and smart mobility.

• Portfolio aligned to future photonics markets, prioritizing organic growth and operational excellence.

• Streamlined structure since 2024, with full plant allocation to business units for efficiency.

• Strong value proposition through leading photonics expertise and deep OEM relationships.

Business segments and market positioning

• Semiconductor & Advanced Manufacturing: Key supplier for wafer fab equipment, €434.4m revenue in 2025, 25.7% EBITDA margin.

• Biophotonics: Supplies global Medtech & Life Science OEMs, €245.4m revenue in 2025, 21.1% EBITDA margin.

• Metrology & Production Solutions: High-end testing for automotive/electronics, €206.7m revenue, 7.8% margin.

• Smart Mobility Solutions: Traffic law enforcement and civil security, €129.7m revenue, 13.6% margin.

Financial performance and investments

• 2025 revenue €1,046.0m, EBITDA €192.5m, free cash flow €152.4m, equity ratio 60.2%.

• Q1 2026: Revenue €241.2m (-1.0% yoy), EBITDA margin 18.4% (up from 14.9%), order intake up 74.4%.

• Highest quarterly order intake in years, driven by major semiconductor order.

• Substantial investments in new production sites, notably Dresden micro-optics fab and Berlin biophotonics site.

• Net debt/EBITDA at 1.6x, with strong financing capacity and robust cash position.